摘要
Abstract
Objective To compare the clinical efficacy and safety of leuprorelin injection and triptorelin injection in the treatment of uterine fibroids. Methods A total of 127 patients with uterine fibroids were randomly divided into control group (n = 56 cases) and treatment group (n = 71 cases) . Control group received triptorelin injection 3. 75 mg per time, intramuscular injection, once every 4 weeks (day 2 of menstrual period) . Treatment group was given leuprorelin injection 3. 75 mg per time, subcutaneous injection, once every 4 weeks (day 2 of menstrual period) . Two groups were treated for 3 times. The clinical efficacy, levels of serum Leptin, vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) , and adverse drug reactions were compared between two groups. Results After treatment, the total effective rates of treatment and control groups were 90. 14％ (64 cases/71 cases) and75. 00％ (42 cases/56 cases) with significant difference (P < 0. 05) .After treatment, the main indexes of treatment and control groups were compared: serum Leptin were (8. 40 ± 1. 17) and (10. 33 ± 1. 28) μg·L-1, VEGF were (72. 59 ± 8. 41) and (92. 66 ± 14. 05) pg·m L-1, IL-8 were (22. 45 ± 2. 62) and (28. 51 ± 3. 73) pg·m L-1, the differences were statistically significant (all P < 0. 05) .The adverse drug reactions of two groups were minor bleeding, hot flushes and skin rashes. The total incidences of adverse drug reactions in the treatment and control groups were 18. 31％ and 25. 00％ without significant difference (P> 0. 05) . Conclusion Leuprorelin injection has a definitive clinical efficacy in the treatment of uterine fibroids, which can significantly reduce the levels of Leptin, VEGF and IL-8, without increasing the incidences of adverse drug reactions.关键词
亮丙瑞林注射液/曲普瑞林注射液/子宫肌瘤/安全性评价Key words
leuprorelin injection/triptorelin injection/uterine fibroids/safety evaluation分类
医药卫生
